Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

A let-7 binding site polymorphism rs712 in the KRAS 3' UTR is associated with an increased risk of gastric cancer.

Li ZH, Pan XM, Han BW, Guo XM, Zhang Z, Jia J, Gao LB.

Tumour Biol. 2013 Oct;34(5):3159-63. doi: 10.1007/s13277-013-0885-x. Epub 2013 Jun 2.

PMID:
23729275
2.

Association of a let-7 KRAS rs712 polymorphism with the risk of breast cancer.

Huang X, Yang Y, Guo Y, Cao ZL, Cui ZW, Hu TC, Gao LB.

Genet Mol Res. 2015 Dec 14;14(4):16913-20. doi: 10.4238/2015.December.14.19.

3.

Lack of association between let-7 binding site polymorphism rs712 and risk of nasopharyngeal carcinoma.

Pan XM, Jia J, Guo XM, Li ZH, Zhang Z, Qin HJ, Xu GH, Gao LB.

Fam Cancer. 2014 Mar;13(1):93-7. doi: 10.1007/s10689-013-9681-4.

PMID:
23996697
4.

A let-7 KRAS rs712 polymorphism increases colorectal cancer risk.

Pan XM, Sun RF, Li ZH, Guo XM, Zhang Z, Qin HJ, Xu GH, Gao LB.

Tumour Biol. 2014 Jan;35(1):831-5. doi: 10.1007/s13277-013-1114-3. Epub 2013 Aug 24.

PMID:
23975373
5.

A variant in 3'-untranslated region of KRAS compromises its interaction with hsa-let-7g and contributes to the development of lung cancer in patients with COPD.

Hu H, Zhang L, Teng G, Wu Y, Chen Y.

Int J Chron Obstruct Pulmon Dis. 2015 Aug 17;10:1641-9. doi: 10.2147/COPD.S83596. eCollection 2015.

6.

Association between a functional polymorphism rs712 within let-7-binding site and risk of papillary thyroid cancer.

Jin H, Liang Y, Wang X, Zhu J, Sun R, Chen P, Nie X, Gao L, Zhang L.

Med Oncol. 2014 Oct;31(10):221. doi: 10.1007/s12032-014-0221-3. Epub 2014 Sep 9.

PMID:
25201577
7.

Association of rs712 polymorphism in Kras gene 3'-luntranslated region and cancer risk: a meta-analysis.

Zhao WH, Qu XF, Xing ZG, Zhao LQ, Qin L, Lv C.

J BUON. 2015 Jan-Feb;20(1):309-16. Review.

PMID:
25778332
8.

A Functional Polymorphism in the Promoter of MiR-143/145 Is Associated With the Risk of Cervical Squamous Cell Carcinoma in Chinese Women: A Case-Control Study.

Liang Y, Sun R, Li L, Yuan F, Liang W, Wang L, Nie X, Chen P, Zhang L, Gao L.

Medicine (Baltimore). 2015 Aug;94(31):e1289. doi: 10.1097/MD.0000000000001289.

9.

A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers.

Christensen BC, Moyer BJ, Avissar M, Ouellet LG, Plaza SL, McClean MD, Marsit CJ, Kelsey KT.

Carcinogenesis. 2009 Jun;30(6):1003-7. doi: 10.1093/carcin/bgp099. Epub 2009 Apr 20.

10.

An let-7 KRAS rs712 polymorphism increases hepatocellular carcinoma risk.

Xiong D, Song YP, Xiong W, Liang YD.

Genet Mol Res. 2015 Oct 30;14(4):14050-5. doi: 10.4238/2015.October.29.24.

11.

Significant association between Let-7-KRAS rs712 G > T polymorphism and cancer risk in the Chinese population: a meta-analysis.

Du XY, Hu YY, Xie C, Deng CY, Liu CY, Luo ZG, Niu YM, Shen M.

Oncotarget. 2017 Feb 21;8(8):13863-13871. doi: 10.18632/oncotarget.14672.

12.

Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases.

Kim M, Chen X, Chin LJ, Paranjape T, Speed WC, Kidd KK, Zhao H, Weidhaas JB, Slack FJ.

Cell Cycle. 2014;13(6):1030-40. doi: 10.4161/cc.27941. Epub 2014 Feb 3.

13.

A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.

Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, Kidd KK, Zhu Y, Christiani DC, Belinsky SA, Slack FJ, Weidhaas JB.

Cancer Res. 2008 Oct 15;68(20):8535-40. doi: 10.1158/0008-5472.CAN-08-2129.

15.

Effects of KRAS mutation and polymorphism on the risk and prognosis of oral squamous cell carcinoma.

Wang WY, Chien YC, Wong YK, Lin YL, Lin JC.

Head Neck. 2012 May;34(5):663-6. doi: 10.1002/hed.21792. Epub 2011 Jun 17.

PMID:
21688344
16.

A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population.

Kazmi HR, Chandra A, Kumar S, Satyam LK, Gupta A, Nigam J, Srivastava M, Mittal B.

J Cancer Res Clin Oncol. 2016 Dec;142(12):2577-2583. Epub 2016 Sep 12.

PMID:
27620744
17.

Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).

Sha D, Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Diasio RB.

Clin Cancer Res. 2014 Jun 15;20(12):3319-27. doi: 10.1158/1078-0432.CCR-14-0069. Epub 2014 Apr 11.

18.

Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families.

Hollestelle A, Pelletier C, Hooning M, Crepin E, Schutte M, Look M, Collee JM, Nieuwlaat A, Dorssers LC, Seynaeve C, Aulchenko YS, Martens JW, van den Ouweland AM, Weidhaas JB.

Breast Cancer Res Treat. 2011 Jul;128(1):79-84. doi: 10.1007/s10549-010-1080-z. Epub 2010 Jul 30.

19.

Genetic polymorphism at miR-181a binding site contributes to gastric cancer susceptibility.

Lin Y, Nie Y, Zhao J, Chen X, Ye M, Li Y, Du Y, Cao J, Shen B, Li Y.

Carcinogenesis. 2012 Dec;33(12):2377-83. doi: 10.1093/carcin/bgs292. Epub 2012 Sep 12.

PMID:
22971574
20.

rs712 polymorphism within let-7 microRNA-binding site might be involved in the initiation and progression of colorectal cancer in Chinese population.

Jiang QH, Peng HX, Zhang Y, Tian P, Xi ZL, Chen H.

Onco Targets Ther. 2015 Oct 22;8:3041-5. doi: 10.2147/OTT.S89746. eCollection 2015.

Supplemental Content

Support Center